secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-04-10T23:59:59+00:00
Accession:  0001193125-23-095819
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics COO Stefani A. Wolff resigns, effective May 2, 2023
----------------------------------------------------------------------

- Stefani A. Wolff notified resignation as COO and EVP of Product Development on April 5, 2023.
- Departure effective May 2, 2023; no successor announced.
- Wolff oversaw product development and operations; departure creates a senior management void.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312523095819/0001193125-23-095819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312523095819/d495127d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-095819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer